NAFLD/NASH: Toward a successful selection of your drug clinical candidate
Fatty liver diseases is a continuous spectrum of progressive and intricate pathological processes, worthening from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH) and possible irreversible evolution to cirrhosis and hepatocellular carcinoma (HCC)
Numbers of drugs are currently under development for the treatment of NAFLD and NASH with various molecular targets leading to different mechanism of actions aimed to address efficiently the hallmarks of the diseases :
- Steatosis and metabolic disorders
- Inflammation and cell death
- Fibrosis and scaring (….)
By preserving the tissue microenvironment, ImaBiotech’s multimodal histological, molecular and bioanalytical technology (molecular and elemental imaging, laser capture microdissection, bioanalysis, multiomics and data science) allows a simultaneous detection, localization and quantification of multiple endogenous biomarkers and exogenous pharmaceutical compounds without any labeling, bringing deeper information about drug localization and its pharmacology effects. This increases the interpretation of drug efficacy and toxicity improving drugs and improving time to market. Here, we will focus on the HFD-mice model to exemplify the power of the combination of the pharmacological and biological approaches, as illustrated below by the strongly consistent translation between metabolic functional test in the animal (Pyruvate Tolerance Test) and the MALDI molecular imaging for glucose on liver section, both showing by complementary approaches the induction of gluconeogenesis by High-Fat Diet.